A new study from the First Hospital of Jilin University in Changchun, published in npj Parkinson’s Disease, aims to fill that gap. Led by Ying Zhang and colleagues, the research team assembled a single-center observational cohort of 301 patients with Parkinson’s disease in Northeast China, a region that has contributed relatively little data to the global genetics-of-Parkinson’s literature. The study’s design was unusually complete for this field: it combined whole-exome sequencing with orthogonal genetic validation, multimodal PET/CT neuroimaging, and longitudinal clinical follow-up stretching over three years. Few cohorts anywhere have tracked GBA1-associated Parkinson’s disease across all three of those dimensions simultaneously.

The numbers are telling. GBA1 variants were identified in 25 of the 301 patients, corresponding to a frequency of 8.31 percent. That figure sits comfortably within the range reported for Chinese and other East Asian cohorts and reinforces a key point: GBA1 is not a rare corner of the Parkinson’s landscape, even in populations historically underrepresented in genetic studies. For a disease affecting millions, roughly one patient in twelve carrying a variant in a single gene is a substantial slice — and one with direct implications for how neurologists counsel and monitor patients.

The investigators compared the 25 patients with GBA1-associated Parkinson’s disease (GBA1-PD) against the remaining patients without GBA1 variants (NGBA1-PD) across a battery of clinical measures. The GBA1 carriers fared worse on several fronts. They showed greater motor impairment, consistent with the picture that has emerged from cohorts in Europe, the Americas, and elsewhere in Asia. They also displayed greater cognitive impairment, echoing one of the most consistent findings in the international literature: GBA1 mutations are among the strongest known predictors of cognitive decline and dementia in Parkinson’s disease.

Two additional clinical signals stand out in the new data. The GBA1-PD group had a higher proportion of patients with the postural instability and gait difficulty, or PIGD, phenotype — the Parkinson’s subtype dominated by balance problems and gait disturbance rather than tremor. PIGD-predominant disease has previously been linked to more rapid progression and poorer outcomes, so its enrichment among GBA1 carriers may be part of the mechanistic bridge between the genetic lesion and the faster disease course reported in prior studies. The GBA1 group also reported worse sleep-related symptoms, adding to growing evidence that the gene’s influence extends beyond the classic motor triad of tremor, rigidity, and bradykinesia into the non-motor domain that increasingly defines life quality in Parkinson’s disease.

Where this study distinguishes itself is in the imaging. Of the full cohort, 176 patients underwent both ¹¹C-CFT PET and ¹⁸F-FDG PET/CT scanning. The ¹¹C-CFT tracer binds to the dopamine transporter, offering a direct, quantitative window into the integrity of the nigrostriatal dopamine system — the very circuitry that Parkinson’s disease progressively destroys. The GBA1-PD patients showed lower striatal ¹¹C-CFT uptake than their non-carrier counterparts, indicating more severe depletion of dopamine transporter binding in the striatum. That finding aligns with the clinical observation of greater motor impairment and suggests that GBA1 variants are associated with a heavier burden of nigrostriatal degeneration, not merely a different clinical presentation of equivalent pathology.

The metabolic imaging told a complementary story. On ¹⁸F-FDG PET, which maps regional glucose consumption as a proxy for neuronal activity, the GBA1-PD group showed reduced metabolism in the precuneus. This posterior medial cortical region is far from a random finding: precuneus hypometabolism is a well-documented imaging correlate of cognitive decline across neurodegenerative diseases, and in Parkinson’s disease it has been repeatedly tied to the emergence of mild cognitive impairment and dementia. Seen together, the two tracers sketch a coherent biological profile — GBA1-associated disease combines deeper dopaminergic denervation with early involvement of posterior cortical networks that support memory and visuospatial function.

The longitudinal arm of the study adds the element most cohorts lack: time. Of the 301 enrolled patients, 271 completed three years of follow-up, allowing the researchers to track how fast each group progressed. Over that period, GBA1-PD patients showed trends toward faster deterioration in both motor function and mood compared with the non-carrier group. The direction of those trends is consistent with the broader literature, in which GBA1 mutations have been associated with accelerated motor and cognitive progression, greater risk of dementia, and higher rates of depression and other affective disturbances.

But here the study delivers one of its most important — and most honest — caveats: after correction for the false discovery rate, a statistical adjustment that guards against spurious positives when many comparisons are tested at once, the longitudinal differences did not remain statistically significant. The trends were there, but the evidence fell short of certainty. That result should temper how the findings are interpreted. It does not overturn the clinical consensus that GBA1-associated disease tends to run a more aggressive course; rather, it underscores that in a cohort of this size, with 25 carriers split across multiple outcome measures over three years, the statistical power to confirm progression differences is limited. Larger, longer, multicenter cohorts will be needed to pin down exactly how much faster GBA1-PD progresses and on which outcomes.

The practical implications remain meaningful. If GBA1-associated Parkinson’s disease carries a recognizable signature — more PIGD-dominant motor disease, more cognitive involvement, more sleep disturbance, deeper striatal dopamine transporter loss, and precuneus hypometabolism — then that signature could serve as the basis for prognostic stratification. Neurologists who identify a GBA1 variant in a newly diagnosed patient could, in principle, use these clinical and imaging markers to anticipate which domains are most likely to decline and to target monitoring and interventions accordingly. This matters acutely as gene-targeted therapies advance: substrate-reduction therapies and other approaches aimed at the glucocerebrosidase pathway encoded by GBA1 are already in clinical testing, and trials of such agents will almost certainly need to enroll, stratify, and follow GBA1-defined subgroups of patients with precision.

The study also carries a demographic message. Most large genetic Parkinson’s cohorts have been assembled in North America and Western Europe, and the field has repeatedly been reminded that variant spectra, carrier frequencies, and even disease presentations can differ across ancestries. By documenting an 8.31 percent GBA1 variant frequency in Northeast China, and by pairing that genetics with PET imaging and longitudinal follow-up, the Jilin team has added a missing piece to the global map. The finding that GBA1-associated disease in this Chinese cohort mirrors the clinical and imaging features reported elsewhere — greater motor and cognitive burden, striatal dopamine transporter loss, precuneus hypometabolism — suggests these are robust, population-independent features of the genotype rather than artifacts of any single health system.

There are, of course, limits to keep in view. The cohort was recruited at a single center, which aids consistency but may constrain generalizability; the number of GBA1 carriers is modest, which explains why the three-year progression trends dissolved under multiple-comparison correction; and the imaging subgroup, at 176 patients, was smaller than the full clinical cohort. None of these limitations undermines the study’s core contribution: a carefully validated, multimodal characterization of GBA1-associated Parkinson’s disease in a population where such data barely existed.

What emerges is a progressively sharpening picture of one gene’s imprint on a complex neurodegenerative disease. GBA1 variants, present in roughly one in twelve Parkinson’s patients in this Northeast Chinese cohort, come bundled with a distinctive profile: more postural instability and gait difficulty, more cognitive impairment, worse sleep, dopaminergic terminals under heavier strain, and posterior cortical networks dimming earlier. Whether that profile translates into definitively faster decline remains an open question that the present data could not fully resolve — but the convergent clinical and imaging evidence already gives clinicians and trial designers a practical framework for identifying the patients most likely to need closer monitoring. In a field racing toward genetically informed medicine, studies like this one are the groundwork.

Subject of Research: Clinical, neuroimaging, and longitudinal characteristics of GBA1-associated Parkinson's disease

Article Title: Clinical, neuroimaging, and longitudinal progression characteristics of GBA1-associated Parkinson’s disease in a Northeast China cohort

Article References: Du, X., Wang, X., Shen, P., Liang, Y., Lin, X., Chen, J., Pan, L., & Zhang, Y. (2026). Clinical, neuroimaging, and longitudinal progression characteristics of GBA1-associated Parkinson’s disease in a Northeast China cohort. npj Parkinson's Disease. https://doi.org/10.1038/s41531-026-01597-0

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01597-0

Keywords: Parkinson's disease, GBA1, genetics, PET imaging, dopamine transporter, neurodegeneration, longitudinal study, cognitive decline, precuneus, whole-exome sequencing, postural instability and gait difficulty, China

The research, led by Amgad Droby of Tel Aviv Sourasky Medical Center together with colleagues at the Feinstein Institutes for Medical Research in New York and collaborators at several other institutions, focused on a question that has haunted the field of neurodegeneration for decades: can we see Parkinson’s disease before it becomes Parkinson’s disease? The answer, according to this work, appears to be a qualified but encouraging yes. The team analyzed 295 resting-state functional MRI datasets drawn from 52 people with early-stage Parkinson’s disease, 92 first-degree relatives who carry Parkinson’s-associated mutations in the GBA1 or LRRK2 genes but show no symptoms, and 58 healthy non-carriers who served as controls.

The technical heart of the study lies in how the researchers processed those scans. Resting-state functional MRI measures spontaneous fluctuations in blood oxygenation across the brain while a person lies still, doing nothing in particular. These fluctuations reveal the brain’s intrinsic functional architecture: the networks of regions that rise and fall in activity together. Rather than examining individual connections one by one, the team used independent component analysis, a mathematical technique that decomposes the massive four-dimensional imaging data into spatial patterns representing distinct functional networks. This approach allows researchers to capture whole-network topographies, the characteristic spatial layouts of brain activity, rather than isolated pairwise links.

What makes this study particularly clever is its borrowing from a different imaging modality. For years, researchers studying Parkinson’s have relied on positron emission tomography with the fluorodeoxyglucose tracer to identify two reproducible metabolic patterns: the Parkinson’s disease-related pattern, known as PDRP, which is elevated in the motor phase of the illness, and the cognition-related pattern, or PDCP, which tracks cognitive decline. These patterns have proven valuable for diagnosis and for measuring disease progression in clinical trials, but PET imaging involves radiation exposure and is expensive and logistically demanding. The central question of the new work was whether equivalent patterns could be extracted from radiation-free MRI scans, and whether they would behave the same way in people who do not yet have symptoms.

To find out, the researchers combined the independent component analysis with a support vector machine, a classical machine learning classifier trained to distinguish the brain patterns of Parkinson’s patients from those of healthy non-carriers. The classifier achieved 87 percent accuracy in that primary discrimination task, with an average accuracy of 78 percent across the full set of group comparisons. Once the classifier had learned to separate the groups, the team applied local interpretable model-agnostic explanations, a technique designed to open the black box of machine learning and reveal which features of the data drove each decision. This step isolated two fMRI-derived patterns that the investigators named fPDRP and fPDCP, the functional analogues of the well-known PET patterns.

With these patterns in hand, the researchers computed expression scores for every participant, essentially asking how strongly each individual’s brain expressed the Parkinson’s-related and cognition-related network topographies. The results were striking. Patients with early Parkinson’s disease showed significantly higher expression of both fPDRP and fPDCP than any of the preclinical groups. But within the preclinical population, an important divergence emerged. Participants classified as having a high likelihood risk, defined as a score of 60 or above on the Movement Disorder Society’s criteria for prodromal Parkinson’s, showed elevated fPDRP expression compared with lower-risk carriers, while their fPDCP expression remained unchanged. In other words, the motor-related network signature appears to rise first, before the cognitive signature, mirroring the clinical course of the disease itself.

Perhaps the most clinically consequential finding concerns what did not matter. Neither the specific genetic mutation a carrier carried, whether GBA1 or LRRK2, nor the status of their cerebrospinal fluid alpha-synuclein seed amplification assay, a molecular test that detects misfolded alpha-synuclein protein, significantly affected network expression in people who already had clinical Parkinson’s disease. This suggests that once the disease manifests, the functional network disruption converges on a common topography regardless of the underlying biology that triggered it. The network patterns, in this sense, capture the final common pathway of the disease rather than its upstream causes.

The team did not stop at cross-sectional analysis. To test whether the fMRI-derived patterns were stable and meaningful over time, they validated their findings in an independent cohort of 33 non-manifesting carriers who had been followed for ten years as part of a long-term observational study. The patterns proved reproducible in this validation cohort, lending weight to the idea that they represent genuine biological signals rather than statistical artifacts. Among the validation participants, eight individuals converted to manifest Parkinson’s disease during the follow-up period. Those converters showed numerically higher baseline fPDRP expression than those who did not convert, though the difference did not reach statistical significance, likely because of the small number of converters. The direction of the effect, however, is exactly what one would hope to see in a genuine preclinical marker.

The implications of this work extend well beyond the laboratory. Drug development for Parkinson’s disease has been repeatedly frustrated by the difficulty of testing therapies in people whose brains are already substantially damaged by the time of diagnosis. A reliable, radiation-free marker of preclinical network disruption could allow trials to enroll people at the earliest stages of the disease process, when interventions have the best chance of altering its trajectory. Because resting-state fMRI involves no ionizing radiation, it could in principle be repeated frequently, enabling researchers to track network changes over time in a way that PET-based measures cannot easily support. The study was supported by Biogen and by the Michael J. Fox Foundation for Parkinson’s Research, both of which have invested heavily in the search for reliable biomarkers of early disease.

Cautions remain, of course. The high-risk group in the preclinical analysis was defined by clinical criteria rather than by certain future diagnosis, and the conversion analysis, while directionally encouraging, involved only eight individuals. The authors themselves note that the fPDRP differences between converters and non-converters were not statistically significant. Still, the convergence of evidence across independent cohorts, multiple genetic risk groups, molecular CSF testing, and a decade of longitudinal follow-up makes a compelling case that the brain’s functional network architecture carries readable information about Parkinson’s disease risk long before the first tremor. For the millions of people who carry Parkinson’s-associated mutations and live with the uncertainty of what the future holds, the prospect of seeing the disease coming, and perhaps one day stopping it before it starts, has moved measurably closer.

Subject of Research: Resting-state fMRI detection of Parkinson's disease-related functional network patterns in preclinical and early disease stages

Article Title: Resting state fMRI network topographies in preclinical and early Parkinson’s disease stages

Article References: Droby, A., Nguyen, N., Do, P., Truong, J., Marebwa, B., Cedarbaum, J. M., Mirelman, A., Eidelberg, D., Vo, A., & Thaler, A. (2026). Resting state fMRI network topographies in preclinical and early Parkinson’s disease stages. npj Parkinson's Disease. https://doi.org/10.1038/s41531-026-01584-5

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01584-5

Keywords: Parkinson's disease, resting-state fMRI, biomarkers, GBA1, LRRK2, machine learning, independent component analysis, PDRP, PDCP, alpha-synuclein, prodromal Parkinson's, neuroimaging

The controversy began with a series of three studies pointing to ITSN1 as a Parkinson’s disease susceptibility gene. Loss-of-function variants are mutations that disable a gene’s protein product, and when such variants occur in ITSN1, the resulting condition is predicted to be haploinsufficiency: having only one working copy of the gene is not enough for normal cellular function. The most recent and most compelling piece of evidence came from Ganoza and colleagues, who screened the Rostock International Parkinson’s Disease study, known as ROPAD, a cohort that includes 8,660 participants with Parkinson’s disease. Their analysis globally replicated the earlier findings and established that ITSN1 loss-of-function carriers represent roughly one to two individuals per thousand with Parkinson’s disease suspected of having a genetic cause.

The scale of the risk elevation is what makes ITSN1 so remarkable. According to the reply, a carrier of an ITSN1 loss-of-function variant faces between five and fifteen times the risk of developing Parkinson’s disease compared with a non-carrier. That places ITSN1 among the strongest genetic risk factors identified for the condition, in a category typically reserved for well-known genes such as LRRK2 and GBA1. Equally notable is the clinical picture: the Parkinson’s disease that emerges in ITSN1 carriers does not differ significantly from classical, non-genetic Parkinson’s disease, meaning carriers present with the familiar motor syndrome rather than an exotic or easily distinguishable variant of the illness.

The Paris team had approached the gene from a different angle. After identifying three pedigrees with ITSN1 loss-of-function variants in their own cohort at the Paris Brain Institute, two of which showed positive segregation of the variant with disease across generations, they hypothesized that ITSN1 might act as a Mendelian gene. In genetics, a Mendelian gene is one in which a single mutation is sufficient to cause disease in a predictable inheritance pattern, typically autosomal dominant or recessive, as opposed to risk genes that merely shift probabilities. If ITSN1 were Mendelian, families carrying one mutation would show the disease appearing in multiple relatives in an orderly pattern, and genetic counseling would follow established rules for dominant disorders.

Ganoza and colleagues tested this hypothesis using the ROPAD data and found it wanting. The frequency of positive family history among ITSN1-associated Parkinson’s disease individuals did not differ significantly from that of individuals without ITSN1 loss-of-function variants: 23 percent versus 34 percent, a difference that failed to reach statistical significance with a p-value of 0.5. On its face, this argues against a straightforward Mendelian model, since a true dominant gene should produce a conspicuously elevated rate of affected relatives. But the Paris group, in their reply, argues that the comparison is less conclusive than it appears, and they raise two methodological concerns that deserve careful attention from anyone following the genetics of neurodegenerative disease.

The first concern involves the composition of the ROPAD cohort itself. The Paris researchers noticed that the frequency of positive family history among non-carriers, 34 percent, seems higher than what would be expected for classical Parkinson’s disease in the general population. The likely explanation, they suggest, is recruitment bias: the cohort was enriched for individuals already suspected of having a genetic etiology for their disease. The authors of the original analysis acknowledged as much, noting that the early average age at onset in their cohort, 55 years, supports the presence of such a bias. Age at onset is a classic marker in Parkinson’s genetics, since earlier-onset disease is more often genetically driven, and a cohort selected for early onset will naturally over-represent familial cases on both sides of any genetic comparison.

The second concern is more fundamental: the ROPAD analysis did not provide pedigrees, or familial structures, for the 13 individuals carrying ITSN1 loss-of-function variants. Without those family trees, the field cannot know how many relatives were actually affected in individuals reporting a positive family history, whether the inheritance pattern suggested autosomal dominance or recessivity, or whether segregation analysis was performed to confirm that the variant tracked with disease. The Paris team offers a plausible alternative explanation for the negative result: several of the loss-of-function variants may have arisen de novo, meaning spontaneously in the carrier rather than being inherited, which would explain why family history was not always positive. There is also growing evidence of reduced penetrance for ITSN1, meaning that not everyone who carries a damaging variant develops disease. Sorting out these possibilities, the reply argues, will be essential before any conclusion can be drawn about the Mendelian hypothesis, and before accurate genetic counseling can be offered to carriers and their relatives.

The counseling challenge is compounded by a feature that makes ITSN1 genuinely unusual among Parkinson’s genes. Loss-of-function variants in ITSN1 are associated not only with Parkinson’s disease but also with neurodevelopmental disorders, conditions that manifest in infancy or childhood. Other recently discovered genes, such as PSMF1 and EPG5, similarly produce a clinical spectrum running from early-onset neurodevelopmental disorders to later-onset Parkinsonism, but in those cases the type of variant usually differs, with truncating variants producing more severe phenotypic consequences than missense variants, which change only a single amino acid. For ITSN1, by contrast, only loss-of-function variants have been reported in Parkinson’s disease, and all are predicted to cause haploinsufficiency. That raises a puzzle the reply states plainly: why could the same mechanism, the loss of one functional copy of the gene, lead to two such distinct phenotypes, a childhood neurodevelopmental disorder in some carriers and a late-life neurodegenerative disease in others?

One hypothesis involves the protein itself. Two isoforms of the ITSN1 protein product, Intersectin-1, are currently known, and the location of a loss-of-function variant, whether it disrupts one isoform or both, could in principle explain the variable expressivity. However, the reply notes that variants identified in both diseases appear to affect both isoforms, so this explanation alone does not suffice, and, as Ganoza and colleagues hypothesized, other modifying factors remain to be discovered. The Paris team sketches several research strategies to find them. Functional studies using biological materials from ITSN1 loss-of-function carriers are already underway to clarify why the loss of Intersectin-1 predisposes to Parkinson’s disease, a question that persists even though the protein’s many roles, particularly as a scaffold for membrane-associated processes such as endocytosis, have been extensively characterized. A second approach would leverage large Parkinson’s disease datasets to compare genetic variant frequencies, environmental exposures, and lifestyle habits between unaffected elderly controls and carriers, with particular attention to ITSN2, the gene encoding the second member of the intersectin family, whose protein can compensate for some defects caused by reduced ITSN1 expression. The consistency of the average age at onset across studies should help researchers choose an appropriate inclusion age for controls. Beyond loss-of-function variants, certain missense variants in the missense-constrained region of the gene, spanning amino acids 1199 to 1722, have been linked to neurodevelopmental disorders, and their possible role in Parkinson’s disease has not yet been explored.

Why does this academic debate matter beyond the laboratory? The reply closes with a warning about clinical practice. Genetic testing is becoming more accessible, and ITSN1 loss-of-function variants are not so rare, so they will increasingly surface as incidental findings in people tested for unrelated reasons. For a neurologically unaffected adult, the counseling challenge resembles that of a pathogenic LRRK2 or severe GBA1 variant, both of which carry elevated risk with incomplete penetrance. But prenatal detection is a different matter entirely. A carrier fetus could face a neurodevelopmental disorder, Parkinson’s disease in later life, or possibly no ITSN1-related neurological disorder at all, a range of outcomes so wide and so uncertain that it could make decisions about pregnancy continuation agonizing for prospective parents. Having confirmed the association between ITSN1 and Parkinson’s disease through the ROPAD replication, the Paris team argues that the field now faces an urgent need to resolve the questions of penetrance, expressivity, and inheritance pattern, not only to advance the science of neurodegeneration but to give families the accurate, honest information they will inevitably demand as this gene enters routine clinical testing.

Subject of Research: Association between ITSN1 loss-of-function variants and Parkinson's disease risk and inheritance

Article Title: Reply to: Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease

Article References: Cogan, G., Tesson, C., Welment, L., Clot, F., LeGuern, E., Lanore, A., Dürr, A., Cormier-Dequaire, F., Debilly, B., Planes, M., Mangone, G., Lesage, S., & Brice, A. (2026). Reply to: Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease. npj Parkinson's Disease, 12(1), Article 236. https://doi.org/10.1038/s41531-026-01470-0

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01470-0

Keywords: Parkinson's disease, ITSN1, genetics, loss-of-function variants, ROPAD study, haploinsufficiency, neurodevelopmental disorders, genetic counseling, reduced penetrance, Mendelian inheritance, LRRK2, GBA1

The story began to unfold in recent years when large-scale genetic studies pointed an unexpected finger at ITSN1. One analysis combining the deCODE, UK Biobank, and Accelerating Medicines Partnership Parkinson’s Disease datasets found that heterozygous loss-of-function variants in the gene, meaning changes that cripple one of the two inherited copies, confer a substantially elevated risk of Parkinson’s disease. A second study described five patients from three families carrying distinct frameshift variants in ITSN1, documenting their clinical pictures in detail. A third effort, drawing on the UK Biobank, the AMP-PD cohort, and the All of Us program, reported a similar increase in risk and even supplied functional evidence from a fruit fly model, showing that the protein encoded by ITSN1, called Intersectin-1, interacts with alpha-synuclein, the sticky protein that clumps in the brains of Parkinson’s patients. What remained unclear was whether patients carrying these variants show a recognizable clinical signature.

To answer that question, the ROPAD team turned to their own trove of data. They analyzed 8,660 reportedly unrelated Parkinson’s disease patients recruited between April 2019 and August 2024, drawn from Europe (68 percent), North America (16 percent), Israel (10 percent), Turkey (4 percent), and South America (2 percent). Crucially, all of these patients had undergone exome or genome sequencing and had no relevant variants in known Parkinson’s genes. That exclusion criterion matters: the researchers removed anyone carrying a pathogenic or likely pathogenic variant in dominant Parkinson’s genes such as LRRK2, SNCA, VPS35, RAB32, or CHCHD2, anyone with two heterozygous or one homozygous pathogenic variant in recessive genes including PARK7, PINK1, and PRKN, and anyone with a pathogenic or risk-factor variant in GBA1, the most common genetic contributor to the disease. By stripping out known genetic explanations, the team could ask whether ITSN1 variants stand on their own as a risk factor.

As a comparison group, the researchers examined 210,657 exome- or genome-sequenced individuals from the CENTOGENE Biodatabank, people referred for routine diagnostic testing, healthy parents in trio analyses, or participants in other observational studies, none of whom had been referred for or diagnosed with Parkinson’s disease. Loss-of-function variants were defined rigorously as start-loss, stop-gain, stop-loss, splice-donor, splice-acceptor, or frameshift changes, identified through a validated in-house bioinformatic pipeline. The team then mined electronic case report forms for clinical details, including year of birth, sex, age at disease onset, age at diagnosis, age at enrollment, family history, and motor scores from a partial Unified Parkinson’s Disease Rating Scale examination.

The result was striking. Thirteen of the 8,660 patients, or 0.15 percent, carried heterozygous loss-of-function variants in ITSN1, compared with just 0.025 percent of the 210,657 comparison individuals. That difference translates into an odds ratio of 6.09, with a 95 percent confidence interval of 3.31 to 11.19 and a p-value of 1.34 times ten to the minus six, a level of statistical significance that is difficult to dismiss. The allele-level comparison tells the same story: the proportion of ITSN1 loss-of-function alleles in the Parkinson’s patients, 0.075 percent, is roughly six times higher than the proportion found in non-Finnish European individuals in the Genome Aggregation Database, the reference catalog that population geneticists use as a baseline for how common variants should be. The enrichment held against every other population in that database as well.

Perhaps most convincing is how neatly these numbers overlap with the earlier studies. The confidence interval from the ROPAD analysis largely overlaps those reported in the two prior association studies, which found odds ratios of 7.3 and 10.5 respectively. The carrier frequency of 0.15 percent in ROPAD matches the 0.15 percent reported in the deCODE-led meta-analysis and the 0.14 percent in the family study. Within the ROPAD cohort itself, ITSN1 loss-of-function variants rank as the sixth most common disease-relevant genetic finding, trailing only variants in GBA1, LRRK2, PRKN, SNCA, and GCH1. For a gene that was essentially invisible to Parkinson’s researchers a few years ago, that is a rapid ascent.

Digging into the variants themselves, the team identified 12 distinct ITSN1 loss-of-function changes among the 13 patients: four nonsense mutations, six frameshift variants, and two splice site changes. Eleven of the twelve appeared only once, and one, a small deletion designated c.2842_2843del, was found in two patients. When the researchers tested whether those two German patients were related, analysis of extended haplotypes found no evidence of close relatedness or a shared founder chromosome, suggesting the variant arose independently in each case. This pattern of largely private, one-off mutations contrasts sharply with the genetics of other dominant Parkinson’s genes, where a handful of recurrent variants, such as the famous LRRK2 G2019S change, account for most cases. It also hints that the mutational spectrum of ITSN1 resembles that of genes where virtually any disruption of the protein is harmful.

There is an intriguing twist. More than 40 distinct ITSN1 loss-of-function variants have already been reported in individuals with autism and neurodevelopmental disorders, and four of the variants found in the ROPAD patients had appeared in that literature. This overlap raises the possibility of pleiotropy, the phenomenon in which a single gene produces different outcomes depending on context. Intersectin-1 is a scaffolding protein involved in clathrin-mediated endocytosis, synaptic vesicle recycling, and actin and CDC42-related signaling, processes essential both for building neural circuits during development and for maintaining them across a lifetime. Losing one functional copy, a state called haploinsufficiency, might disturb neurodevelopmental circuitry in childhood or undermine neuronal maintenance later in life. Which outcome prevails may depend on genetic modifiers, the residual expression produced by splice-altering variants, environmental stressors, and other factors scientists have yet to untangle.

On the clinical side, the ROPAD analysis found that patients carrying ITSN1 variants look, in most respects, like ordinary Parkinson’s patients. The male-to-female ratio, the proportion with a positive family history, the age at diagnosis, the age at enrollment, and the disease duration all failed to differ significantly between carriers and non-carriers. A multiple linear regression of motor scores adjusted for disease duration also found no significant difference, though the p-value of 0.075 leaves open the possibility of a subtle effect. Interestingly, the two earlier large-cohort studies did report significantly younger ages at onset among carriers, with mean or median onsets in the early sixties versus around seventy in non-carriers. The ROPAD cohort as a whole skews young, with a mean and median onset of 55 years, which likely explains why the same signal did not emerge here. Notably, the median onset of 53 years among ROPAD carriers is comparable to the 47-year average onset in the five family-study patients, and one ROPAD participant carried both an ITSN1 deletion and a mild GBA1 variant, a combination the researchers excluded from their main analysis because the GBA1 change may have modified her disease risk, echoing what has been documented in people carrying both LRRK2 and GBA1 variants.

Taken together, the findings cement ITSN1 as a genuine Parkinson’s disease gene, one that produces a form of the illness clinically indistinguishable from idiopathic disease. The authors propose the designation PARK-ITSN1 for this genetic entity and call for further research into its natural history and treatment responses, questions that will matter as genetic testing becomes routine and as pharmaceutical companies design trials stratified by genotype. The study also carries a broader lesson about the power of deeply curated clinical and genetic datasets: when a diagnostic laboratory pairs sequencing with systematic phenotyping across thousands of patients, even vanishingly rare risk factors, present in fewer than two people per thousand, can be detected, validated, and connected to the biology of one of the world’s most common neurodegenerative diseases.

Subject of Research: Association between ITSN1 loss-of-function variants and Parkinson's disease risk in the ROPAD cohort

Article Title: Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease

Article References: Ganoza, C. A., Westenberger, A., Paul, J. J., Curado, F., Somerville, E. N., Rennecke, J., Bauer, P., & Beetz, C. (2026). Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease. npj Parkinson's Disease, 12(1), Article 237. https://doi.org/10.1038/s41531-026-01562-x

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01562-x

Keywords: Parkinson's disease, ITSN1, genetics, loss-of-function variants, ROPAD study, haploinsufficiency, Intersectin-1, neurodegeneration, exome sequencing, age at onset, GBA1, pleiotropy

The strongest case for this idea comes from genetics. Over the past twenty years, researchers hunting for genes that cause or raise the risk of neurodegenerative disorders have repeatedly landed on the endolysosomal system, the network of vesicles and organelles that ferries cargo to lysosomes for destruction. In Parkinson disease, the evidence is particularly compelling. A substantial proportion of genes linked to the condition encode proteins that are essential for lysosomal health, and the two most common genetic causes of Parkinson disease, mutations in GBA1 and LRRK2, both converge on lysosomal biology. Remarkably, both of these pathways are now being targeted in clinical trials, marking one of the first times that fundamental cell biology has been translated so directly into therapeutic strategies for a neurodegenerative illness.

The GBA1 story illustrates how a single gene can illuminate an entire disease mechanism. GBA1 encodes glucocerebrosidase, a lysosomal enzyme that breaks down fatty substances called glucosylceramides. People who carry one mutated copy of the gene are at markedly elevated risk of developing Parkinson disease, and studies have shown that reduced glucocerebrosidase activity in the substantia nigra, the brain region that degenerates in Parkinson disease, is associated with increased levels of alpha-synuclein, the protein that clumps into the Lewy bodies that define the disorder. Work from the Krainc laboratory and others has revealed a bidirectional loop: deficient glucocerebrosidase impairs the degradation of alpha-synuclein, while accumulating alpha-synuclein in turn blocks the delivery of fresh glucocerebrosidase to lysosomes, creating a vicious cycle of worsening protein aggregation and deepening lysosomal failure.

LRRK2, the other major Parkinson gene, tells a complementary story. This large kinase enzyme phosphorylates a family of Rab GTPases that regulate membrane trafficking throughout the cell. When lysosomes are damaged, LRRK2 is recruited to their surface through pathways involving the CASM machinery and GABARAP proteins, where it helps coordinate membrane repair and the removal of damaged lysosomal material. Pathogenic LRRK2 mutations boost kinase activity, producing enlarged lysosomes with reduced degradative capacity and impairing the clearance of alpha-synuclein. Because LRRK2 is also active in immune cells, its dysfunction extends to microglia, the brain’s resident immune cells, linking lysosomal failure to the neuroinflammation that accompanies neurodegeneration. LRRK2 kinase inhibitors, including the molecule BIIB122, have already been tested in patients, and a broad initiative called the LRRK2 investigative therapeutics exchange is working to overcome the remaining obstacles to translating this biology into disease-modifying therapies.

Beyond these headline genes, the review catalogues an expanding roster of lysosomal proteins implicated in Parkinson disease. Mutations in VPS35, a core component of the retromer complex that sorts cargo through endosomes, cause familial Parkinson disease and disrupt the retrieval of the chaperone-mediated autophagy receptor LAMP2A, which neurons use to deliver alpha-synuclein to lysosomes for destruction. ATP13A2, a lysosomal transporter whose loss causes an early-onset form of parkinsonism, exports polyamines from the lysosome, and its deficiency triggers lysosomal dysfunction and alpha-synuclein accumulation. The lysosomal ion channel TMEM175, identified through genome-wide association studies as a risk factor, regulates the proton balance that keeps lysosomes acidic enough for their digestive enzymes to function. Even the recently characterized Commander complex has emerged as a regulator of lysosomal function and Parkinson disease risk. Each of these discoveries reinforces the same message: many independent genetic insults funnel into a single vulnerable pathway.

In Alzheimer disease, the lysosomal connection takes a somewhat different form, centered on the endocytic trafficking machinery. Enlarged endosomes packed with amyloid-beta are among the earliest pathological changes detectable in neurons of people with Alzheimer disease, appearing before amyloid plaques form. The strongest genetic link is SORL1, which encodes the receptor SORLA, a key regulator of cargo trafficking through the endolysosomal system, including trafficking of the amyloid precursor protein. Loss-of-function variants in SORL1 substantially increase Alzheimer risk, and depletion of SORLA in human neurons impairs endosomal traffic even independently of amyloidogenic processing. Other risk genes, including BIN1, PICALM and CD2AP, all participate in endocytosis and endosomal sorting, and presenilin mutations that cause familial Alzheimer disease disrupt lysosomal acidification and autophagy, although the precise role of presenilins in this process remains debated.

The lipid-carrying protein APOE adds another layer to the Alzheimer picture. The APOE4 allele, the strongest common genetic risk factor for late-onset disease, promotes the accumulation of cholesterol in lysosomes of astrocytes, impairs mitochondrial function and dampens autophagy through multiple mechanisms, including direct binding of ApoE4 to gene regulatory elements that control autophagy genes. Meanwhile, TREM2, a receptor on microglia that depends on lysosomal processing for its function, shapes how immune cells respond to amyloid plaques, although a recent clinical trial targeting TREM2 failed, underscoring how much remains to be learned about translating lysosomal biology into treatments.

Frontotemporal dementia and amyotrophic lateral sclerosis, two clinically distinct disorders with heavily overlapping genetics, supply perhaps the most direct evidence that autophagy, the cellular self-eating process that delivers cargo to lysosomes, is essential for neuronal survival. Multiple ALS and FTD genes encode proteins that regulate autophagy at different steps: TBK1 and OPTN coordinate the selective removal of damaged mitochondria; VCP and UBQLN2 participate in extracting ubiquitinated proteins for degradation; SQSTM1, also known as p62, serves as a cargo receptor that tags aggregates for autophagic clearance; and C9ORF72, the most common genetic cause of both diseases, forms a complex that regulates Rab GTPases and mTORC1 signaling at the lysosome. Mutations in CHMP2B, part of the ESCRT-III machinery that repairs ruptured lysosomal membranes, cause a distinctive form of frontotemporal dementia characterized by lysosomal storage pathology, and recent work shows that the ALS-linked proteins annexin A11 and CHMP2B act sequentially in membrane repair.

Progranulin, encoded by the GRN gene, has become a focal point for therapeutic development in frontotemporal dementia. Haploinsufficiency, meaning that carriers of a single mutated GRN copy produce only half the normal amount of the protein, causes familial FTD and produces features resembling neuronal ceroid lipofuscinosis, a classic lysosomal storage disease. Progranulin supports lysosomal homeostasis through multiple mechanisms: it promotes lysosomal acidification, acts as a chaperone for the enzyme cathepsin D, facilitates the processing of prosaposin into saposins that activate lipid-degrading enzymes, and supports glucocerebrosidase activity. The risk gene TMEM106B, which regulates lysosomal size, motility and stress responses, modifies disease penetrance in GRN mutation carriers, and strikingly, TMEM106B itself was recently discovered to form amyloid fibrils in aged brains across multiple neurodegenerative diseases. Progranulin augmentation strategies, including an antibody called latozinemab that raises progranulin levels and AAV gene therapy, are already in clinical trials, with interim results reported for the gene therapy approach.

What emerges from this synthesis is a view of neurodegeneration as, at its core, a failure of cellular housekeeping that unfolds over decades. Neurons are uniquely vulnerable because they live as long as the organism, rely heavily on long-range transport of lysosomes along axons, and generate toxic metabolic byproducts such as oxidized dopamine that further damage lysosomes. The convergence of genetic evidence from four major disease families onto the endolysosomal system suggests that therapies aimed at restoring lysosomal health, whether by enhancing enzyme activity, improving acidification, boosting autophagic flux or repairing damaged lysosomal membranes, could offer benefits that span diagnostic boundaries. With GBA1 and LRRK2 trials underway in Parkinson disease, progranulin augmentation advancing in frontotemporal dementia and lysosome-targeting small molecules in preclinical development, the humble lysosome has moved from the margins of neuroscience to the center of the search for disease-modifying treatments.

Subject of Research: Lysosomal dysfunction as a mechanism of neurodegenerative disease

Article Title: Lysosomal dysfunction in neurodegenerative disease

Article References: Brooker, S. M., Coukos, R., & Krainc, D. (2026). Lysosomal dysfunction in neurodegenerative disease. Nature Reviews Neurology. https://doi.org/10.1038/s41582-026-01262-3

Image Credits: AI Generated

DOI: 10.1038/s41582-026-01262-3

Keywords: lysosome, neurodegeneration, Parkinson disease, Alzheimer disease, frontotemporal dementia, amyotrophic lateral sclerosis, GBA1, LRRK2, autophagy, progranulin, alpha-synuclein, endolysosomal trafficking

TIMP2 belongs to a family of endogenous inhibitors that restrain matrix metalloproteinases, a group of enzymes that remodel the extracellular matrix, the molecular scaffolding that surrounds and supports cells throughout the body. In the brain, this remodelling machinery is far more than passive infrastructure. It governs synaptic plasticity, the migration and repair of cells, inflammatory responses, and the clearance of protein aggregates. When the balance between metalloproteinases and their inhibitors tips, the consequences can include blood-brain barrier disruption, aberrant synaptic pruning, and the deposition of misfolded proteins such as amyloid-beta and alpha-synuclein, both central suspects in neurodegenerative disease.

TIMP2 has an especially intriguing pedigree. Earlier work by a different research group showed that delivering TIMP2-rich plasma from human umbilical cord blood into aged mice revitalised hippocampal function, suggesting the protein carries rejuvenating signals. Subsequent studies demonstrated that neuronal TIMP2 regulates hippocampus-dependent plasticity and extracellular matrix complexity, and that the protein declines with age. Conversely, postmortem analyses of brain tissue from Parkinson’s disease patients have documented altered expression of matrix metalloproteinases and their inhibitors, hinting that the remodelling system is disturbed in the disorder. What remained unclear was whether TIMP2 measurable in living patients reflects Parkinson’s disease processes, ageing, or both, and whether genetic variation in TIMP2 shapes clinical outcomes.

To address these questions, Milan Zimmermann, Kathrin Brockmann, Benjamin Roeben and colleagues measured TIMP2 concentrations in cerebrospinal fluid from 480 patients with Parkinson’s disease, 67 patients with dementia with Lewy bodies and 16 control participants. Dementia with Lewy bodies was included because it sits on a clinical continuum with Parkinson’s disease, sharing the aggregation of alpha-synuclein while differing in the timing and prominence of cognitive decline. The team also stratified patients according to their status in the GBA1 gene, mutations in which are among the most common and best characterised genetic risk factors for Parkinson’s disease and are known to accelerate cognitive deterioration and influence alpha-synuclein profiles in cerebrospinal fluid.

The study was designed to interrogate TIMP2 from two complementary angles. Cross-sectional analyses compared TIMP2 concentrations with clinical scales measuring cognition, motor function and depression, and with established cerebrospinal fluid biomarkers including beta-amyloid 1-42, total tau, phosphorylated tau, neurofilament light chain and alpha-synuclein. Longitudinal analyses then followed patients over time, grouping them by tertiles of TIMP2 concentration and by selected single nucleotide polymorphisms within the TIMP2 gene, to determine whether the protein or its genetic variants predicted the onset of cognitive impairment or the pace of motor decline.

The cross-sectional results were telling. Cerebrospinal fluid TIMP2 levels rose with age and correlated with markers of neurodegeneration, converging on the idea that the protein tracks the degenerative state of the nervous system. Sex differences emerged as well: male Parkinson’s disease patients showed higher TIMP2 levels than their female counterparts, and female dementia with Lewy bodies patients carrying GBA1 mutations exhibited elevated TIMP2 compared with controls. Sex-related differences in matrix metalloproteinase biology are increasingly recognised across cardiovascular and neurological disease, and these data suggest they extend to the TIMP2 axis in synucleinopathies.

Longitudinally, TIMP2 concentrations did not significantly predict whether or when patients developed cognitive impairment, tempering the hope that the protein alone could serve as a straightforward prognostic marker for dementia in Parkinson’s disease. However, the motor domain offered a more nuanced picture. Among Parkinson’s disease patients carrying GBA1 mutations, higher TIMP2 levels were linked to increased postural instability, one of the axial motor features most closely associated with disease progression and falling risk. This connection is biologically plausible: postural instability reflects widespread brainstem and cortical involvement, processes in which extracellular matrix remodelling and neuroinflammatory cascades are deeply implicated.

The genetic analyses, though explicitly exploratory, may prove to be the study’s most provocative contribution. Specific variants within the TIMP2 gene, notably the single nucleotide polymorphisms rs1384364 and rs8068674, were associated with more favourable cognitive outcomes or delayed motor progression. In the key summary points accompanying the paper, the authors report that male patients with particular TIMP2 SNP genotypes exhibited delayed onset of cognitive impairment, higher scores on the Montreal Cognitive Assessment, or later onset of postural instability. If these findings replicate, they would suggest that inherited differences in how the extracellular matrix remodelling system is tuned help explain the notorious clinical heterogeneity of Parkinson’s disease, in which some patients remain cognitively intact for decades while others decline rapidly.

Taken together, the study’s central conclusion is one of careful reattribution. Rather than functioning as a disease-specific biomarker of Parkinson’s disease, cerebrospinal fluid TIMP2 appears to primarily reflect ageing-related processes intertwined with neurodegeneration. This distinction matters for how biomarkers are interpreted in clinical trials. Drugs targeting alpha-synuclein or GBA1, for example, would be poorly served by a surrogate endpoint that fluctuates mainly with chronological age. Conversely, if interventions designed to slow brain ageing or restore youthful extracellular matrix dynamics are to be developed, TIMP2 could serve as a pharmacodynamic readout of whether such strategies are engaging their intended biology. The authors suggest that TIMP2 quantification and its associated genetic variants show promise as biomarkers of pathological ageing, potentially informing therapeutic strategies for neurodegenerative diseases more broadly.

Several caveats frame the results. The control group was small, the genetic associations were exploratory and require replication in independent and larger cohorts, and cerebrospinal fluid sampling, while informative, is an invasive procedure that limits population-scale deployment. The interplay between TIMP2 in cerebrospinal fluid and its activity within brain parenchyma also remains to be fully mapped, as do the mechanistic consequences of the associated variants on protein expression or function. Nonetheless, by bridging a protein celebrated for rejuvenating aged mouse brains with the clinical realities of hundreds of Parkinson’s disease and dementia with Lewy bodies patients, the Tübingen team has supplied concrete human evidence that extracellular matrix-related ageing mechanisms are woven into the fabric of neurodegeneration. In doing so, the study adds momentum to a growing research movement that views Parkinson’s disease not simply as a disorder of misfolded proteins, but as a condition in which the ageing environment of the brain, its scaffolding, its plasticity reserves and its remodelling enzymes, determines how the disease ultimately expresses itself.

Subject of Research: TIMP2 cerebrospinal fluid levels and genetic variants as biomarkers of ageing and neurodegeneration in Parkinson's disease

Article Title: Exploring TIMP2 genetics and CSF levels in Parkinson’s disease: biomarkers of neurodegeneration and ageing

Article References: Zimmermann, M., Fandrich, M., Schulte, C., Jakobi, M., Wurster, I., Lerche, S., Zimmermann, S., Deuschle, C., Schneiderhan-Marra, N., Joos, T. O., Gasser, T., Brockmann, K., & Roeben, B. (2026). Exploring TIMP2 genetics and CSF levels in Parkinson’s disease: biomarkers of neurodegeneration and ageing. GeroScience. https://doi.org/10.1007/s11357-026-02495-2

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02495-2

Keywords: TIMP2, Parkinson's disease, dementia with Lewy bodies, cerebrospinal fluid biomarkers, matrix metalloproteinases, extracellular matrix, GBA1, neurodegeneration, ageing, cognitive impairment, postural instability, GeroScience